Papilloma virus infection
The latest analysis of a vaccine’s safety, efficacy and immunogenicity indicates that Cervarix, a human papilloma virus (HPV) vaccine offers sustained protection for over six years against infection by viral types HPV-16 and HPV-18, most commonly associated with cervical cancer.